This pharma stock is surging despite weak Q2FY23 result

The stock is down 24.6 per cent in the last 6 months, however, it is up more than 7 per cent in just the last five trading sessions.

On October 27, the shares of Jubilant Pharmova Ltd surged 3.35 per cent and closed at Rs 348.5. The stock opened at Rs 337.2 and made an intraday high and low of Rs 356.05 and Rs 337.2, respectively.     

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments- Pharmaceuticals, Drug discovery & development solutions, and Proprietary novel drugs. On October 22, the company announced its latest September quarter results.  

For Q2FY23, its consolidated net revenue from operations decreased by 3 per cent YoY to Rs 1584.74 crore, from Rs 1213 crore in Q2FY22. EBITDA declined by 35.57 per cent YoY to Rs 218 crore from Rs 339.50. Q2FY23 PAT came in at Rs 7.58 crore compared to Rs 144.03 crore a year ago, a drop of 95 per cent.  

In terms of shareholding, the promoter owns 50.67 per cent of the company, FIIs own 23.06 per cent, DIIs own 1.6 per cent, and non-institutional investors own the remaining 24.59 per cent. 

The company has a market capitalisation of Rs 5550 crore and belongs to BSE group A. It is trading at a PE multiple of 68.7x. The scrip has a 52-week high and low of Rs 356.05 and Rs 337.2, respectively.    

The stock is down 24.6 per cent in the last 6 months, however, it is up more than 7 per cent in just the last five trading sessions.